Trefoil Therapeutics to Present Update on Regenerative Treatments for Corneal Diseases

SAN DIEGO--(BUSINESS WIRE)--Trefoil Therapeutics announced today it will provide an update on the company and its clinical program for TTHX1114 at the upcoming Eyecelerator virtual conference. TTHX1114 is the company’s first-in-class, engineered fibroblast growth factor 1 (FGF-1), for the regenerative treatment of corneal diseases. The company presentation will be on November 6 in the track beginning at 1:30PM ET / 10:30AM PT.

TTHX1114, administered by intracameral (behind the cornea) injection, is currently undergoing a Phase 1/2 clinical study (INTREPID trial) to assess its safety and ability to regenerate corneal endothelial cells lost due to corneal endothelial dystrophies, including Fuchs endothelial corneal dystrophy. The company plans to begin a second clinical trial in later stage Fuchs patients by year-end. Trefoil also has a topical product based on its engineered FGF-1 that is in preclinical development for the treatment of corneal epithelial disorders. This topical product is expected to begin clinical trials in the second half of 2021.

FGF-1 is a naturally occurring protein with a well-established ability to stimulate cell proliferation and migration as well as protect cells from stress and injury. TTHX1114 has been engineered to enable its use as a pharmaceutical.

The Eyecelerator conference (www.eyecelerator.com) is organized by the American Academy of Ophthalmology and American Society of Cataract and Refractive Surgery to showcase emerging technology, groundbreaking research and inventive concepts in ophthalmology.

About Trefoil Therapeutics

Trefoil Therapeutics is a private biotechnology company focused on leveraging its engineered fibroblast growth factor-1 protein technology platform to develop first-in-class pharmacologic treatments for serious corneal endothelial diseases and epithelial disorders. Trefoil’s lead product candidate is TTHX1114, an engineered form of FGF-1 designed to stimulate corneal endothelial cell proliferation and migration, thereby reversing vision loss caused by CED. The technology underlying Trefoil’s platform was developed by co-founder Michael Blaber, Ph.D., and is licensed from Florida State University.